Advertisement

Agents and Actions

, Volume 41, Supplement 1, pp C104–C105 | Cite as

Antihistaminic drug bromadryl and stimulated platelet aggregation

  • R. Nosál
  • V. Jančinová
  • M. Petríková
Histamine and Diverse Cell Types

Abstract

The H1-receptor antagonist bromadryl dosedependently inhibited stimulated rat platelet aggregationin vitro. Bromadryl was 10 times more effective on the secondary aggregation of thrombin-stimulated platelets compared with its inhibition of ADP-stimulated primary platelet aggregation in plasma. The inhibition of aggregation was accompanied by a dose-dependent inhibition of thrombin-stimulated malondialdehyde formation and thromboxane B2 production. The results indicate that bromadryl may interfere intracellularly with membrane phospholipid peroxidation and the arachidonic acid metabolism of stimulated platelets. Bromadryl, like other cationic amphiphilic drugs, may inhibit stimulated platelet functions by decreasing the stimulus-induced activation of phospholipase A2. Our results support the possible interference of bromadryl with histamine as an intraplatelet messenger responsible for aggregation.

Keywords

Arachidonic Acid Platelet Aggregation Arachidonic Acid Metabolism Antihistaminic Drug Secondary Aggregation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. [1]
    V. Jančinová and R. Nosáĺ,Cimetidine and ketotifen inhibit stimulated aggregation and histamine liberation from rabbit blood platelets. Agents and Actions27, 135–137 (1989).PubMedGoogle Scholar
  2. [2]
    V. Jančinová, M. Petríková and R. Nosáĺ,The antihistaminic drug cimetidine and arachidonic acid metabolism. Agents and Actions, Spec. Conf. Issue, C434–C436 (1992).Google Scholar
  3. [3]
    S. P. Saxena, L. J. Brandes, A. B. A. B. Becker, K. J. Simons, F. S. La Bella and J. M. Gerrard,Histamine is an intracellular messenger mediating platelet aggregation. Science243, 1596–1599 (1989).PubMedGoogle Scholar
  4. [4]
    R. Nosáĺ, V. Jančinová and M. Petríková,Antiaggregatory properties of beta-adrenoceptor blocking drugs are related to their physico-chemical properties. Platelets3, 29–33 (1992).Google Scholar
  5. [5]
    R. Nosál, M. Petríková and V. JančinováAlterations in lipid peroxidation of thrombin stimulated rat platelets treated with beta-adrenoceptor blocking drugs. J. Lipid Med.8, 121–132 (1993).Google Scholar
  6. [6]
    R. Nosáĺ, V. Jančinová and M. Petríková,On the relationship between the inhibition of thrombin stimulated aggregation and thromboxane formation in isolated platelets treated with betaadrenoceptor blocking drugs. Thromb. Res.68, 333–344 (1992).PubMedGoogle Scholar
  7. [7]
    W. Siess,Molecular mechanisms of platelet activation. Physiol. Rev.69, 58–179 (1989).PubMedGoogle Scholar
  8. [8]
    B. Gachályi, K. Tihanyi, A. Vas and A. Kaldor,In vitro effect of cimetidine on ADP induced platelet aggregation and thromboxane A 2 synthesis in man. Thromb. Res.35, 105–109 (1984).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1994

Authors and Affiliations

  • R. Nosál
    • 1
  • V. Jančinová
    • 1
  • M. Petríková
    • 1
  1. 1.Institute of Experimental PharmacologySlovak Academy of SciencesBratislavaSlovakia

Personalised recommendations